Clinical Trial Update: Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps [Phase 3]

View source ↗

Summary

Phase 3 safety study of intranasal fluticasone propionate 400 mcg twice daily using a novel bidirectional device in chronic rhinosinusitis with or without nasal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinosinusitis Without Nasal Polyps
• Rhinosinusitis with Nasal Polyps

Drugs mentioned

• Fluticasone propionate (Fluticasone propionate)

Snippet

Sponsor: Optinose US Inc. | Conditions: Chronic Sinusitis With or Without Nasal Polyps | Phase 3 | Status: COMPLETED | Results posted: 2016-03-01